Action CHGCY CHUGAI PHARMACEUTICAL CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Chugai Pharmaceutical Co., Ltd. OTC Markets

Actions

CHGCY

US1712691039

Marché Fermé - OTC Markets
Autres places de cotation
 21:59:59 28/06/2024 		Varia. 5j. Varia. 1 janv.
17,77 USD -1,77 % Graphique intraday de Chugai Pharmaceutical Co., Ltd. +10,65 % -5,73 %
24/06 Le Nikkei japonais termine la séance agitée sur une note plus forte RE
24/06 L'indice Nikkei du Japon progresse dans une séance agitée RE

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Chugai Pharmaceutical : Announcement of a Director Resignation
PU
Chugai Pharmaceutical : All pages, single page [PDF
PU
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO in the UK and Ireland
AQ
Chugai Pharmaceutical - Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System, Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
AQ
Chugai Pharmaceutical - Maruho Announces Launch of Mitchga Subcutaneous Injection 30mg Vials in Japan
AQ
Chugai Pharmaceutical : Collaborative Research for Advanced Data Linkage between Electronic Medical Records and Clinical Trial Data Collection System Expedited Transcription at the Medical Institution and for SDV in the Pharmaceutical Company
PU
Chugai Pharmaceutical : Personnel Changes
PU
Chugai Pharmaceutical : Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Provide Information on Detection of Copy Number Alterations of Cancer-Related Genes and bTMB Score
PU
Chugai, NCCH, OMPU and MICIN Start Company-Sponsored Phase I Study in Oncology with a New Decentralized Clinical Trial Structure, Improving access to the clinical trial for patients far from the institution
AQ
Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
Chugai Announces 2024 1st Quarter Results
AQ
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)
PU
Chugai Pharmaceutical : F. Hoffmann-La Roche Announces First Quarter Sales 2024
PU
Chugai Pharmaceutical Co., Ltd. - Positive Phase III Results Showed Vabysmo Improved Vision for the First Time in Japanese in Angioid Streaks
AQ
Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Earthquake off the Eastern Coast of Taiwan
AQ
Chugai Obtains Approval for FoundationOne CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for the AKT Inhibitor, Capivasertib for Advanced HR-positive, HER2-negative Breast Cancer
AQ
Chugai Pharmaceutical : Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
PU
Chugai Obtains Regulatory Approval for Vabysmo, the Only Bispecific Antibody in the Ophthalmology Field, for Additional Indication of Macular Edema Associated with Retinal Vein Occlusion
AQ
Chugai Pharmaceutical - Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials
AQ
Chugai Obtains Regulatory Approval for 'Piasky 340mg' for Paroxysmal Nocturnal Hemoglobinuria in Japan
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 4519
  4. Action CHGCY
  5. Actualités Chugai Pharmaceutical Co., Ltd.
  6. Communiqués